Mirum PharmaceuticalsMEX:MIRM 46 Current Ratio is 2.09 as of Mar. 2026, which is 52% below its 10-year median of 4.32. GuruFocus rates MEX:MIRM with a GF Score™ of 46/100 and a GF Value™ of MXN812.06. The stock has 5 warning signs investors should review. Among 1,410 Biotechnology companies, Mirum Pharmaceuticals ranks worse than 67.38% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Mirum Pharmaceuticals's current ratio for the quarter that ended in Mar. 2026 was 2.09.
Mirum Pharmaceuticals has a current ratio of 2.09. It generally indicates good short-term financial strength.
The historical rank and industry rank for Mirum Pharmaceuticals's Current Ratio or its related term are showing as below:
MEX:MIRM'
s Current Ratio Range Over the Past 10 Years
Min: 2.09 Med: 4.32 Max: 21.22
Current: 2.09
During the past 8 years, Mirum Pharmaceuticals's highest Current Ratio was 21.22. The lowest was 2.09. And the median was 4.32.
MEX:MIRM's Current Ratio is ranked worse than 67.38% of 1410
companies
in the Biotechnology industry
Industry Median: 3.89
vs MEX:MIRM: 2.09
Mirum Pharmaceuticals (MEX:MIRM) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Mirum Pharmaceuticals Current Ratio Related Terms
Mirum Pharmaceuticals Current Ratio Historical Data
* Premium members only.
The historical data trend for Mirum Pharmaceuticals's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MIRM vs RYTM, SYRE, PTGX: Current Ratio Comparison
For the Biotechnology subindustry, Mirum Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mirum Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Mirum Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirum Pharmaceuticals (MEX:MIRM) has a Current Ratio of 2.09 as of Mar. 2026. This is 52% below median its historical median of 4.32. Over the past decade, Mirum Pharmaceuticals' Current Ratio has ranged from 2.09 to 21.22. According to the industry distribution chart, Mirum Pharmaceuticals ranks #950 out of 1410 companies in the Biotechnology industry, placing it in the top 67.4%.
Is Mirum Pharmaceuticals' Current Ratio too high?
Mirum Pharmaceuticals' current Current Ratio of 2.09 is 52% below median its 10-year median of 4.32. Over the past 10 years, this metric has ranged from a low of 2.09 to a high of 21.22. The Biotechnology industry median Current Ratio is 3.89. Mirum Pharmaceuticals' value of 2.09 is 46.3% below this industry median. Based on the distribution chart, Mirum Pharmaceuticals ranks #950 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Mirum Pharmaceuticals has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Current Ratio compare to RYTM and SYRE?
According to the Biotechnology industry distribution chart, Mirum Pharmaceuticals ranks #950 out of 1410 companies for Current Ratio. This places Mirum Pharmaceuticals in the lower half of its industry. The industry median Current Ratio is 3.89. Mirum Pharmaceuticals' value of 2.09 is 46.3% below this benchmark. Historically, Mirum Pharmaceuticals' own Current Ratio has ranged from 2.09 to 21.22 over the past decade. While the company's 10-year median is 4.32 vs. the industry median of 3.89, Mirum Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mirum Pharmaceuticals's current Current Ratio of 2.09 is 46.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mirum Pharmaceuticals's current Current Ratio is 2.09, which is 52% below median its own 10-year median of 4.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Mirum Pharmaceuticals (MEX:MIRM) has a current Current Ratio of 2.09. The stock's GF Value™ is MXN812.06, compared to a current price of MXN1,256.12 — trading 54.7% above its estimated fair value. The current Current Ratio is 2.09, which is 52% below median its 10-year median of 4.32 and 46.3% below the Biotechnology industry median of 3.89. Mirum Pharmaceuticals' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Mirum Pharmaceuticals (MEX:MIRM), the current Current Ratio is 2.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mirum Pharmaceuticals (MEX:MIRM) Overvalued in 2026?
Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,256.12 is trading 54.7% above its estimated GF Value™ of MXN812.06.
Key valuation signals for MEX:MIRM:
Current Ratio: 2.09 (52% below median its 10-year median of 4.32)
GF Value™: MXN812.06 vs. price of MXN1,256.12 (54.7% above fair value)
Industry Position: 46.3% below the Biotechnology median (#950 of 1410)
No single metric tells the full story. See the MEX:MIRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
46GF Score
Get the complete analysis for MEX:MIRM
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MIRM has been successfully added to your 
